Telemus Capital LLC grew its stake in shares of Celgene Co. (NASDAQ:CELG) by 2.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 26,123 shares of the biopharmaceutical company’s stock after acquiring an additional 574 shares during the quarter. Telemus Capital LLC’s holdings in Celgene were worth $2,727,000 as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. Janus Henderson Group PLC grew its holdings in shares of Celgene by 4,290.5% in the second quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock valued at $1,092,071,000 after purchasing an additional 8,217,433 shares in the last quarter. BlackRock Inc. boosted its stake in Celgene by 5.7% during the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after buying an additional 3,084,227 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in Celgene by 1,489.2% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,907,052 shares of the biopharmaceutical company’s stock worth $247,669,000 after buying an additional 1,787,052 shares during the period. Vanguard Group Inc. boosted its stake in Celgene by 3.1% during the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock worth $6,951,579,000 after buying an additional 1,610,056 shares during the period. Finally, Jennison Associates LLC boosted its stake in Celgene by 11.5% during the third quarter. Jennison Associates LLC now owns 14,962,407 shares of the biopharmaceutical company’s stock worth $2,181,818,000 after buying an additional 1,546,673 shares during the period. Hedge funds and other institutional investors own 78.67% of the company’s stock.
Several research firms recently weighed in on CELG. Vetr upgraded Celgene from a “buy” rating to a “strong-buy” rating and set a $116.84 price objective for the company in a report on Thursday, January 25th. Mizuho set a $128.00 target price on shares of Celgene and gave the stock a “buy” rating in a report on Tuesday, December 26th. BTIG Research reiterated a “hold” rating on shares of Celgene in a report on Tuesday, January 23rd. BidaskClub upgraded Celgene from a “sell” rating to a “hold” rating in a research note on Tuesday, December 12th. Finally, Citigroup reiterated a “hold” rating on shares of Celgene in a research report on Friday, December 22nd. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $128.22.
Celgene Co. (NASDAQ:CELG) traded up $0.05 during midday trading on Wednesday, hitting $91.61. The stock had a trading volume of 6,721,036 shares, compared to its average volume of 8,075,558. Celgene Co. has a 12 month low of $86.55 and a 12 month high of $147.17. The company has a debt-to-equity ratio of 2.29, a quick ratio of 4.80 and a current ratio of 4.99. The firm has a market capitalization of $68,980.00, a PE ratio of 17.45, a price-to-earnings-growth ratio of 0.65 and a beta of 1.58.
Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.78 by $0.09. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The firm had revenue of $3.48 billion during the quarter, compared to the consensus estimate of $3.46 billion. During the same quarter in the previous year, the business earned $1.61 earnings per share. The firm’s quarterly revenue was up 16.9% compared to the same quarter last year. analysts forecast that Celgene Co. will post 7.66 EPS for the current fiscal year.
Celgene declared that its Board of Directors has initiated a share repurchase plan on Wednesday, February 14th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company’s board believes its stock is undervalued.
In related news, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $95.99, for a total value of $887,907.50. Following the completion of the transaction, the director now directly owns 94,801 shares of the company’s stock, valued at approximately $9,099,947.99. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mark J. Alles acquired 3,260 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The stock was acquired at an average cost of $91.90 per share, with a total value of $299,594.00. Following the completion of the acquisition, the insider now directly owns 178,904 shares in the company, valued at $16,441,277.60. The disclosure for this purchase can be found here. Insiders sold 41,120 shares of company stock valued at $3,879,509 in the last three months. 0.95% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Celgene Co. (CELG) Shares Bought by Telemus Capital LLC” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://ledgergazette.com/2018/03/14/celgene-co-celg-stake-increased-by-telemus-capital-llc.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.